Use of c-src inhibitors alone or in combination with sti571...

A - Human Necessities – 61 – K

Patent

Rate now

  [ 0.00 ] – not rated yet Voters 0   Comments 0

Details

A61K 31/506 (2006.01) A61K 31/519 (2006.01) A61K 45/00 (2006.01) A61P 35/02 (2006.01) A61P 43/00 (2006.01)

Patent

CA 2450777

The invention relates to a combination which comprises (a) at least one compound decreasing the c-Src activity and (b) N-{5-[4-(4-methyl-piperazino- methyl)-benzoylamdio]-2-methylphenyl}-4-(3-pyridyl)-2-pyrimidine-amine or the monomethanesulfonate salt thereof; to pharmaceutical compositions comprising said combinations; and to a method of treating a warm-blooded animal having leukaemia, especially chronic myelogenous leukaemia, comprising administering to the animal at least one compound inhibiting the activity of a member of the Src kinase family,the Tec kinase family or a Raf kinase inhibitor, in particular inhibiting the c-Src protein tyrosine kinase activity or inhibiting simultaneously the c-Src protein tyrosine kinase activity and the Bcr-Abl tyrosine kinase activity, alone or in combination with a Bcr-Abl inhibitor, in particular N-{5-[4-(4-methyl-piperazino-methyl)-benzoylamido]-2-methylphenyl}- 4-(3-pyridyl)-2-pyrimidine-amine.

L'invention concerne une combinaison qui comporte (a) au moins un composé diminuant l'activité de c-Src et (b) N-{5-[4-(4-méthyl-pipérazino-méthyl)-benzoylamido]-2-méthylphényl}-4-(3-pyridyl)-2-pyrimidine-amine ou le sel monométhanesulfonate de celui-ci, des compositions pharmaceutiques comprenant lesdites combinaisons; et un procédé de traitement d'un animal à sang chaud souffrant de leucémies, en particulier la leucémie myélogène chronique, qui consiste à administrer à l'animal au moins un composé inhibant l'activité d'un élément de la famille des kinases Src, la famille des kinases Btk, la famille des kinases Tec ou un inhibiteur des kinases Raf, inhibant en particulier l'activité de la protéine tyrosine kinase c-Src ou, simultanément, l'activité de la protéine tyrosine kinase c-Src et l'activité de la tyrosine kinase Bcr-Abl, seul ou en combinaison avec un inhibiteur Bcr-Abl, en particulier N-{5-[4-(4-méthyl-pipérazino-méthyl)-benzoylamido]-2-méthylphényl}-4-(3-pyridyl)-2-pyrimidine-amine.

LandOfFree

Say what you really think

Search LandOfFree.com for Canadian inventors and patents. Rate them and share your experience with other people.

Rating

Use of c-src inhibitors alone or in combination with sti571... does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Use of c-src inhibitors alone or in combination with sti571..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Use of c-src inhibitors alone or in combination with sti571... will most certainly appreciate the feedback.

Rate now

     

Profile ID: LFCA-PAI-O-1676022

  Search
All data on this website is collected from public sources. Our data reflects the most accurate information available at the time of publication.